• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Lenvatinib mesylate Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759328

Lenvatinib mesylate is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Lenvatinib mesylate, Inhibitor
Full Product Name
Lenvatinib mesylate
Product Synonym Names
E7080 (mesylate)
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
522.96
Solubility
DMSO: 8mg/mL (15.2mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C22H23ClN4O7S
SMILES
CS(O)(=O)=O.COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O
CAS Number
857890-39-2
Target & IC50
VEGFR2: ic50 4nM
VEGFR3: ic50 5.2nM
VEGFR1: ic50 22nM
FGFR1: ic50 46nM
PDGFRalpha: ic50 51nM
PDGFRbeta: ic50 39nM
c-Kit: ic50 100nM

Product References and Citations for Lenvatinib mesylate, inhibitor

Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361.
Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361.
Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545.
Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545.
Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment,of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173.
Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment,of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173.

Other Notes

Small volumes of Lenvatinib mesylate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Lenvatinib mesylate purchase

MBS5759328 is an inhibitor targeting Lenvatinib mesylate.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000